Risk Stratification in Chronic Lymphocytic Leukemia
The Role of the Clinical Laboratory
Introduction
November 2008
Welcome to Mayo Medical Laboratories' Hot Topics. These presentations provide short discussions of current topics and may be helpful to you in your practice.
Our speaker for this program is Dr. Curtis Hanson, from the Division of Hematopathology at Mayo Clinic. Dr. Hanson will discuss the various test options for risk stratification in chronic lymphocytic leukemia (CLL). This is the second of two presentations on CLL and laboratory testing. View Part 1.
Introduction |
Jump to section:
- Goals Today
- Risk Assessment
- Risk Assessment in CLL
- CLL Rai Stage: Treatment Free
- CLL: Nodular Pattern of BM Infiltration
- CLL: Pattern of BM Infiltration
- Blood: Prognostic Indicators
- CLL and Fragile Cells
- CLL: Fragile Cells and Time to Treatment
- CLL Prognostics: CD38
- CLL Rai Stage 0: CD38
- ZAP-70 in B-CLL
- ZAP-70 in B-CLL: Detection
- ZAP-70 in B-CLL: Questions
- ZAP-70 by Flow in CLL
- ZAP-70 by Flow in CLL
- ZAP-70 by Flow in CLL
- ZAP-70: Immunohistochemistry
- CLL Rai Stage 0: ZAP-70
- CD49d in CLL
- CD49d: Clinical Role
- Time to Treatment (TTT) & Overall Survival (OS) from Diagnosis*
- CD49d in CLL
- CD49d in CLL
- Immunoglobulin Variable (IgVH) Region Mutation Status
- IgVH Sequencing
- CLL Rai Stage 0: IgVH
- Chromosome Anomalies in Chronic Lymphocytic Leukemia
- Distribution of Chromosome Anomalies in CLL Detected by FISH
- 13q-: A Microdeletion in B-CLL
- Overall Survival: By FISH Anomaly
- Risk Assessment in CLL: Summary
- Risk Assessment In CLL
- Risk Assessment
- Goals Today
- Questions?
External
link
PDF
document
Excel
document
Word
document